These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM. Cancer; 2003 Sep 01; 98(5):888-93. PubMed ID: 12942553 [Abstract] [Full Text] [Related]
4. [Chronic myelogenous leukemia]. Ohnishi K. Gan To Kagaku Ryoho; 2001 Sep 01; 28(9):1199-205. PubMed ID: 11579630 [Abstract] [Full Text] [Related]
5. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation. Steegmann JL, Casado LF, Tomás JF, Sanz-Rodríguez C, Granados E, de la Cámara R, Alegre A, Vázquez L, Ferro MT, Figuera A, Arranz R, Fernández-Rañada JM. Bone Marrow Transplant; 1999 Mar 01; 23(5):483-8. PubMed ID: 10100563 [Abstract] [Full Text] [Related]
6. Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia. Kantarjian HM, Talpaz M. Semin Oncol; 1994 Dec 01; 21(6 Suppl 14):8-13. PubMed ID: 7992099 [Abstract] [Full Text] [Related]
7. [Recent progress in therapy for chronic myelogenous leukemia]. Urabe A. Gan To Kagaku Ryoho; 1997 Jul 01; 24(9):1066-73. PubMed ID: 9239158 [Abstract] [Full Text] [Related]
8. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group. Ohnishi K, Minami S, Ueda T, Nishimura M, Tsubaki K, Takemoto Y, Takeshita A, Sao H, Kageyama S, Ueda R, Ohno R. Int J Hematol; 2000 Aug 01; 72(2):229-36. PubMed ID: 11039674 [Abstract] [Full Text] [Related]
9. [Value of interferon-alpha in treatment of chronic myeloid leukemia]. Thaler J. Acta Med Austriaca; 1993 Aug 01; 20(3):65-9. PubMed ID: 8368048 [Abstract] [Full Text] [Related]
14. [Interferon therapy for chronic myelogenous leukemia]. Shibata A, Hashimoto S. Gan To Kagaku Ryoho; 1993 Feb 01; 20(2):200-6. PubMed ID: 8434957 [Abstract] [Full Text] [Related]
15. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP, International Randomised Study of Interferon versus STI571 (IRIS) Study Group. N Engl J Med; 2003 Oct 09; 349(15):1423-32. PubMed ID: 14534335 [Abstract] [Full Text] [Related]
16. Comparative analysis of two consecutive phase II studies with IFN-alpha and IFN-alpha + ara-C in untreated chronic-phase CML patients. Austrian CML Study Group. Thaler J, Hilbe W. Bone Marrow Transplant; 1996 May 09; 17 Suppl 3():S25-8. PubMed ID: 8769696 [Abstract] [Full Text] [Related]
19. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H. Cancer; 2003 Sep 15; 98(6):1105-13. PubMed ID: 12973833 [Abstract] [Full Text] [Related]